- Home
- ETB vs RGNX Comparison
ETB vs RGNX Comparison
Compare ETB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETB
- RGNX
- Stock Information
- Founded
- ETB 2005
- RGNX 2008
- Country
- ETB United States
- RGNX United States
- Employees
- ETB N/A
- RGNX 353
- Industry
- ETB Investment Bankers/Brokers/Service
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETB Finance
- RGNX Health Care
- Exchange
- ETB Nasdaq
- RGNX Nasdaq
- Market Cap
- ETB 437.4M
- RGNX 445.5M
- IPO Year
- ETB N/A
- RGNX 2015
- Fundamental
- Price
- ETB $14.73
- RGNX $8.82
- Analyst Decision
- ETB
- RGNX Strong Buy
- Analyst Count
- ETB 0
- RGNX 8
- Target Price
- ETB N/A
- RGNX $28.50
- AVG Volume (30 Days)
- ETB 71.8K
- RGNX 692.5K
- Earning Date
- ETB 01-01-0001
- RGNX 08-07-2025
- Dividend Yield
- ETB 8.23%
- RGNX N/A
- EPS Growth
- ETB N/A
- RGNX N/A
- EPS
- ETB N/A
- RGNX N/A
- Revenue
- ETB N/A
- RGNX $155,782,000.00
- Revenue This Year
- ETB N/A
- RGNX $327.08
- Revenue Next Year
- ETB N/A
- RGNX N/A
- P/E Ratio
- ETB N/A
- RGNX N/A
- Revenue Growth
- ETB N/A
- RGNX 74.95
- 52 Week Low
- ETB $11.59
- RGNX $5.04
- 52 Week High
- ETB $14.08
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- ETB 59.43
- RGNX 54.02
- Support Level
- ETB $14.40
- RGNX $7.35
- Resistance Level
- ETB $14.66
- RGNX $9.25
- Average True Range (ATR)
- ETB 0.12
- RGNX 0.54
- MACD
- ETB 0.02
- RGNX 0.08
- Stochastic Oscillator
- ETB 71.43
- RGNX 74.62
About ETB Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.